C3i Center Inc. has received regulatory approval in the form of a Drug Establishment License (DEL) to commercially produce cell therapies, making it the first CDMO in Canada to achieve this milestone.   The approval follows an inspection by the cell and gene therapy experts from Health Canada. The DEL approval recognizes C3i as having industry-leading expertise, regulatory know-how, and strong quality standards.   “The C3i team worked hard to meet the requirements of a DEL and are proud that...